On Jume 1, 2023 GI Biome, an affiliate of GI Innovation and a microbiome drug development company, reported that it has started administering GB-X01 to the first patient in the domestic phase 1 clinical trial for colorectal cancer microbiome treatment (Press release, GI Biome, JUN 1, 2023, View Source [SID1234633251]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This clinical trial will be conducted at Samsung Seoul Hospital for patients who have completed standard treatment after radical resection of colorectal cancer. It is planned to evaluate the safety and tolerability of GB-X01 and to confirm changes in the composition of the intestinal microflora before and after administration. It is expected to secure phase 1 results in the second half of this year, including a 4-week dosing period for a total of 9 patients (up to 18) and a 4-week follow-up period thereafter. GB-X01

, obtained through GI Biome’s platform, has a single strain isolated from an adult female as its main component. As an oral drug, the antitumor effect was confirmed in monotherapy and combination therapy. It was said that ‘5-FU’, the most commonly used chemical anticancer drug for the treatment of colorectal cancer, showed a synergistic effect in combination with target anticancer drugs such as bevacizumab and natural killer (NK) cells under development by GI Cell . Based on these preclinical results, we applied for domestic and international patents on materials and uses. The company also confirmed through preclinical studies that it relieves anticancer drug-induced diarrhea ( CID ), which is a typical side effect of anticancer treatment, leading to treatment delay, dose reduction, and treatment discontinuation. A phase 2 plan for mitigating gastrointestinal side effects caused by the toxicity of chemical anticancer drugs is also taking shape.

When phase 1 is completed in the second half of this year, the goal is to apply for phase 2 in Korea early next year. In phase 2, it plans to evaluate the anticancer efficacy through the improvement of side effects caused by chemotherapy and the combination therapy of immune cell therapy.

On June 1, 2023 Triumvira Immunologics presented its corporate presentation (Presentation, Triumvira Immunologics, JUN 1, 2023, View Source [SID1234632480]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 2, 2023 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, reported that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer, will present at the 2023 Jefferies Global Healthcare Conference in New York, NY on Thursday, June 8, 2023 at 11:00 am ET (Press release, Bicara Therapeutics, JUN 1, 2023, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-to-present-at-the-2023-jefferies-global-healthcare-conference [SID1234632400]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 2, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, reported that management will present at the following investor conferences in June (Press release, Immunocore, JUN 1, 2023, View Source [SID1234632391]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference
Fireside Chat: Wednesday, June 7, 2023, at 4:00 p.m. EDT
Goldman Sachs Annual Healthcare Conference
Fireside Chat: Wednesday, June 14, 2023, at 1:20 p.m. PDT
The presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the events, a replay of the presentations will be made available for a limited time.

On June 1, 2023 invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, reported that it has completed a second tranche of investment in pHion Therapeutics ("pHion"), a next-generation mRNA vaccine company (Press release, InvoX Pharma, JUN 1, 2023, View Source [SID1234632380]). The transaction supports invoX’s strategy to be a fully integrated biopharmaceutical company and its ongoing commitment to deliver innovative life-saving therapies

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo, irrespective of size, into nanoparticles that are highly efficient at cellular entry and can outperform currently available technologies. Compared with traditional mRNA vaccine delivery platforms, the RALA platform has the added advantage of ease of scalability and logistics, including stability at room temperature.

Under the leadership of CEO and Founder, Prof Helen McCarthy, pHion has made significant progress since invoX’s initial investment in June 2021, with advances made across all pre-clinical programs and the establishment of a laboratory in Belfast, Northern Ireland for the production of pHion’s mRNA vaccines. The additional investment will support growth of the company’s proprietary RALA platform with an immediate focus on the advancement of pHion’s lead project, PTX_V1, into clinical trials in the first half of 2024. PTX_V1 is a first-in-class therapeutic vaccine for the treatment of human papilloma virus (HPV)-related cancers. Infection with HPV is responsible for approximately 90% of cervical cancers and up to 70% of oropharyngeal cancers, with a high unmet clinical need. pHion’s pipeline also includes differentiated therapeutic vaccines for the treatment of ovarian (PTX_V5) and prostate (PTX_V3) cancers.

This investment has received all required regulatory approvals, including clearance from the regulatory agency in charge of enforcing the U.K.’s National Security and Investment Act, testimony to invoX’s continued willingness to build trust and work closely with regulators.